ACS Biomaterials Science & Engineering,
Journal Year:
2024,
Volume and Issue:
10(11), P. 6814 - 6827
Published: Oct. 5, 2024
DNA
is
a
kind
of
flexible
and
versatile
biomaterial
for
constructing
nanostructures
nanodevices.
Due
to
high
biocompatibility
programmability
easy
modification
fabrication,
nanotechnology
has
emerged
as
powerful
tool
application
in
intracellular
targeted
protein
degradation.
In
this
review,
we
summarize
the
recent
advances
design
mechanism
degradation
technologies
such
hydrolysis
chimeras,
lysosomal
autophagy
based
Subsequently,
introduce
nanotechnologies
cascade
circuits,
nanostructures,
dynamic
machines.
Moreover,
present
latest
developments
Finally,
vision
challenges
are
discussed.
Materials Today Bio,
Journal Year:
2025,
Volume and Issue:
30, P. 101443 - 101443
Published: Jan. 5, 2025
Glioblastoma
(GBM)
is
the
most
prevalent
primary
malignant
brain
tumor,
characterized
by
a
high
mortality
rate
and
poor
prognosis.
The
blood-brain
barrier
(BBB)
blood-tumor
(BTB)
present
significant
obstacles
to
efficacy
of
tumor-targeted
pharmacotherapy,
thereby
impeding
therapeutic
potential
numerous
candidate
drugs.
Targeting
delivery
adequate
doses
drug
across
BBB
treat
GBM
has
become
prominent
research
area
in
recent
years.
This
emphasis
driven
exploration
evaluation
diverse
technologies
for
with
some
already
undergoing
clinical
trials.
review
provides
thorough
overview
advancements
challenges
targeted
treatment.
It
specifically
emphasizes
systemic
administration
strategies
assess
their
limitations
Furthermore,
this
highlights
promising
future
directions
development
intelligent
systems
aimed
at
overcoming
current
enhancing
against
GBM.
These
not
only
support
foundational
on
but
also
offer
methodological
approaches
applications.
Materials Today Bio,
Journal Year:
2025,
Volume and Issue:
31, P. 101457 - 101457
Published: Jan. 5, 2025
Central
nervous
system
(CNS)
diseases
are
a
major
cause
of
disability
and
death
worldwide.
Due
to
the
blood-brain
barrier
(BBB),
drug
delivery
for
CNS
is
extremely
challenging.
Nano-delivery
systems
can
overcome
limitations
BBB
deliver
drugs
CNS,
improve
ability
target
brain
provide
potential
therapeutic
methods
diseases.
At
same
time,
choice
different
(bypassing
or
crossing
BBB)
further
optimize
effect
nano-drug
system.
This
article
reviews
nano-delivery
way
enters
brain.
Different
kinds
nanoparticles
were
discussed
in
depth.
Acta Neuropathologica Communications,
Journal Year:
2025,
Volume and Issue:
13(1)
Published: Feb. 5, 2025
The
incidence
of
pituitary
adrenocorticotropic
hormone
(ACTH)-secreting
PitNETs,
commonly
known
as
ACTH
is
significantly
higher
in
females;
however,
the
underlying
causes
for
this
gender
disparity
remain
unclear.
In
study,
we
analyzed
expression
deubiquitinating
enzymes
functioning
PitNETs
from
both
male
and
female
subjects
using
RNA
sequencing
identified
USP11
a
potential
susceptibility
factor
contributing
to
prevalence
these
females.
Further
investigation
revealed
that
markedly
elevated
with
levels
than
those
observed
normal
tissue.
Experimental
data
indicate
promotes
transcription
proopiomelanocortin
(POMC)
secretion
ACTH.
contrast,
knockdown
leads
substantial
reduction
POMC
secretion,
demonstrated
vitro
vivo
models.
Mechanistically,
found
facilitates
deubiquitination
key
TPIT
enhancing
its
protein
stability
thereby
promoting
secretion.
Additionally,
virtual
screening
Lomitapide
Nicergoline
inhibitors
USP11,
reducing
Thus,
emerges
therapeutic
target,
drugs
aimed
at
inhibiting
function
could
benefit
women
Cushing's
disease.
Aggregate,
Journal Year:
2024,
Volume and Issue:
unknown
Published: July 8, 2024
Abstract
Chemodynamic
therapy
(CDT)
has
shown
promising
antitumor
effects
in
various
malignant
tumors.
However,
its
application
for
glioblastoma
(GBM)
is
significantly
hindered
by
the
challenge
of
delivering
CDT
agents
across
blood‐brain
barrier
(BBB)
and
achieving
efficient
tumor
targeting.
To
overcome
these
obstacles,
this
study
presents
a
novel
DNA
nanomachine
(Cu@tFNAs‐G‐A
NM)
loading
copper
ions
(Cu
2+
)
onto
tetrahedral
framework
nucleic
acids
(tFNAs)
functionalized
with
dual
aptamers.
The
aptamers
(GS24
BBB
penetration
AS1411
targeting)
empowered
Cu@tFNAs‐G‐A
NM
ability
to
effectively
penetrate
selectively
accumulate
cells.
Upon
internalization,
loaded
Cu
reacted
tumor‐overexpressed
reductive
glutathione
(GSH)
hydrogen
peroxide
(H
2
O
),
generating
hydroxyl
radicals
(·OH)
inducing
cell
death.
Additionally,
was
found
be
rapidly
cleared
from
brain
normal
tissues
within
24
h,
minimizing
potential
systemic
toxic
side
effects.
These
findings
demonstrate
effective
against
GBM
open
up
new
avenues
development
targeted
therapies
GBM.
Biomolecules,
Journal Year:
2024,
Volume and Issue:
14(8), P. 960 - 960
Published: Aug. 7, 2024
Cardiovascular
diseases
(CVDs)
are
one
of
the
leading
causes
death
worldwide.
Despite
significant
advances
in
current
drug
therapies,
issues
such
as
poor
targeting
and
severe
side
effects
persist.
In
recent
years,
nanomedicine
has
been
extensively
applied
research
treatment
CVDs.
Among
these,
biomembrane-modified
biomimetic
nanodrug
delivery
systems
(BNDSs)
have
emerged
a
focus
due
to
their
unique
biocompatibility
efficient
capabilities.
By
modifying
with
biological
membranes,
BNDSs
can
effectively
reduce
recognition
clearance
by
immune
system,
enhance
circulation
time
vivo,
improve
targeting.
This
review
first
provides
an
overview
classification
pathological
mechanisms
CVDs,
then
systematically
summarizes
progress
discussing
design
principles,
functional
characteristics,
clinical
application
potential.
Finally,
it
highlights
challenges
faced
translation
BNDSs.
Cancers,
Journal Year:
2024,
Volume and Issue:
16(19), P. 3300 - 3300
Published: Sept. 27, 2024
Glioblastoma
(GBM)
is
a
prevalent
type
of
malignancy
within
the
central
nervous
system
(CNS)
that
associated
with
poor
prognosis.
The
standard
treatment
for
GBM
includes
surgical
resection
tumor,
followed
by
radiotherapy
and
chemotherapy;
yet,
despite
these
interventions,
overall
outcomes
remain
suboptimal.
blood–brain
barrier
(BBB),
which
plays
crucial
role
in
maintaining
stability
brain
tissue
under
normal
physiological
conditions
CNS,
also
poses
significant
obstacle
to
effective
delivery
therapeutic
agents
GBMs.
Recent
preclinical
studies
have
demonstrated
nanomedicine
systems
(NDDSs)
offer
promising
results,
demonstrating
both
targeting
safety,
thereby
presenting
potential
solution
targeted
drug
delivery.
In
this
review,
we
first
explore
various
strategies
employed
overcome
BBB
Subsequently,
results
clinical
translation
NDDSs
are
summarized,
highlighting
progress
made.
Finally,
discuss
advancing
development
accelerating
their
translational
research
through
well-designed
trials
therapy.
Advanced Science,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Feb. 28, 2025
Abstract
Chemoresistance
represents
a
major
challenge
for
osteosarcoma
treatment.
Despite
the
improved
knowledge
of
cancer
biology,
core
determinants
cisplatin
(DDP)
resistance
in
remain
unclear
and
deserve
further
exploration.
Here,
RFWD3
is
identified
as
key
regulator
DDP
sensitivity
using
genome‐wide
CRISPR
screen.
It
demonstrated
that
overexpressed
post‐chemotherapy
tissues
compared
to
pre‐chemotherapy
tissues.
Knocking
out
increased
cells
Mechanistically,
bound
ubiquitinated
PHGDH
at
Lys137
residue,
promoting
its
degradation
conserving
cellular
oxidized
nicotinamide
adenine
dinucleotide
(NAD
+
).
The
resulting
surplus
NAD
enhanced
TCA
cycle,
leading
production
aspartic
acid
glutamic
de
novo
nucleotide
biosynthesis.
In
addition,
virtual
screening
techniques
are
employed
identify
Lomitapide
specific
inhibitor
RFWD3‐PHGDH
interaction,
capable
disrupting
binding
between
PHGDH.
found
exhibits
significant
synergistic
anti‐osteosarcoma
effect
when
combined
with
DDP.
conclusion,
role
regulating
metabolism
revealed
comprised
targetable
candidates
overcoming
chemoresistance
osteosarcoma.
ABSTRACT
Cancer
research
predominantly
centers
on
diagnosis,
treatment,
and
elucidation
of
underlying
mechanisms.
Nevertheless,
the
intricate
nature
tumor
genesis
development
has
rendered
early
diagnostic
therapeutic
outcomes
less
than
optimal,
making
conquest
a
formidable
challenge.
The
interdisciplinary
fusion
medicine
engineering,
termed
“intersection
engineering”,
emerged
as
groundbreaking
paradigm,
offering
novel
avenues
for
advancing
cancer
studies.
As
this
approach
evolves,
it
yielded
numerous
breakthroughs
in
mechanistic
exploration.
In
review,
we
summarize
how
intersection
engineering
propels
progress
by
leveraging
combined
strengths
medicine,
bioinformatics,
materials
science,
artificial
intelligence.
This
addresses
limitations
traditional
diagnostics
therapies,
such
low
sensitivity,
poor
efficacy,
significant
side
effects,
challenges
associated
with
Moreover,
highlight
global
cutting‐edge
advancements
potential
future
directions
field.
